These agents include semaglutide (Ozempic for diabetes, Wegovy for obesity), liraglutide (Victoza for diabetes, Saxenda for obesity), dulaglutide (Trulicity, diabetes only), and tirzepatide (Mounjaro for diabetes, Zepbound for obesity)with tirzepatide being a dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 receptor agonist
No se recomienda combinar agonistas GLP-1 con inhibidores de DPP-4, ya que esta combinacin rara vez aporta beneficio adicional
The challenged laws required PBMs and covered entities to admit any willing pharmacy into their pharmacy networks while prohibiting them from incentivizing plan participants to use specific pharmacies via differential copays or other financial incentives
Its regenerative properties extend to cardiovascular health, where it aids in tissue repair and may help reduce the risk of cardiovascular disease
Cardiometabolic Risk Factors: Greater improvements in cardiometabolic risk factors compared to those taking a placebo